\u0627\u0644\u0648\u0637\u0646\u064a \u0644\u0645\u062e\u062a\u0628\u0631\u0627\u062a \u0627\u0644\u0635\u062d\u0629 \u0627\u0644\u0639\u0627\u0645\u0629 \u0646\u0638\u0627\u0645<\/span><\/p>\n Biosafety Governance and Containment Risk Framework<\/span><\/p>\n Strategic Advisory \u2022 Biosafety Governance Design \u2022 Containment Policy Framework \u2022 Risk-Based Laboratory Operations<\/span><\/p>\n A national health authority overseeing multiple diagnostic and research laboratories sought to strengthen governance over activities involving high-consequence pathogens. Laboratories across the system operated under different containment environments ranging from containment level 2 (CL2) diagnostic laboratories to facilities capable of CL3 and CL4 operations.<\/span><\/p>\n Although biosafety regulations were in place, operational practices and containment decisions varied between institutions. This variability created uncertainty regarding which laboratory activities should be conducted within specific containment environments and increased the complexity of biosafety oversight.<\/span><\/p>\n DealBridge Global was engaged to design a risk-based containment governance framework capable of standardizing laboratory activity rules across CL2, CL3, and CL4 facilities. The objective was to ensure that diagnostic and research activities involving infectious materials were performed within the appropriate containment environment while strengthening biosafety governance and regulatory compliance.<\/span><\/p>\n Through a structured biosafety assessment and governance design process, DealBridge developed a containment framework that aligned pathogen risk, laboratory activities, and containment requirements across the national laboratory system.<\/span><\/p>\n The national laboratory system included a network of clinical laboratories, specialized research facilities, and high-containment laboratories supporting infectious disease diagnostics, pathogen surveillance, and biomedical research.<\/span><\/p>\n CL2 laboratories supported routine diagnostic testing involving moderate-risk pathogens commonly encountered in clinical laboratories. CL3 laboratories handled airborne infectious agents requiring enhanced containment procedures, while a limited number of facilities possessed high-containment capabilities required for the most hazardous pathogens.<\/span><\/p>\n While biosafety regulations existed, laboratory institutions often interpreted containment requirements differently. This led to variations in how certain laboratory activities involving infectious materials were performed across the system.<\/span><\/p>\n Public health authorities were also increasingly focused on improving preparedness for emerging infectious diseases. Ensuring that laboratory activities were performed within appropriate containment environments became a critical priority for national biosafety governance.<\/span><\/p>\n Leadership therefore recognized the need for a clearer framework defining which diagnostic and research activities should occur at each containment level based on pathogen risk and operational considerations.<\/span><\/p>\n The primary challenge facing the laboratory system was operational clarity across containment environments.<\/span><\/p>\n Laboratories across the network had different containment capabilities and infrastructure designs, making it difficult to apply biosafety guidance consistently.<\/span><\/p>\n In some situations, laboratory personnel lacked clear operational guidance regarding which activities required CL3 containment rather than CL2 environments. Emerging pathogens also introduced new uncertainty regarding containment requirements for diagnostic and research activities.<\/span><\/p>\n Without a structured governance framework, containment decisions could vary between laboratories, creating potential biosafety and regulatory risks.<\/span><\/p>\n Addressing these challenges required a risk-based containment governance model capable of aligning laboratory activities with appropriate biosafety environments.<\/span><\/p>\n DealBridge structured the containment governance initiative around a framework linking biosafety challenges with operational clarity.<\/span><\/p>\n Variation in biosafety practices across laboratories<\/span> Risk-based containment activity classification<\/span> Consistent containment practices across laboratories<\/span> DealBridge implemented a structured governance design process addressing biosafety risk classification, containment policy development, and oversight mechanisms.<\/span><\/p>\n DealBridge conducted an assessment of containment capabilities across laboratories, including facility infrastructure, biosafety procedures, personnel training, and regulatory compliance. This evaluation provided a system-wide understanding of biosafety readiness.<\/span><\/p>\n A risk classification framework was developed to guide containment decisions based on pathogen characteristics such as transmissibility, disease severity, and availability of medical countermeasures.<\/span><\/p>\n Operational rules were defined specifying which diagnostic and research activities should occur within CL2, CL3, or CL4 containment environments. These rules addressed laboratory procedures such as specimen processing, pathogen culture, experimental research, and advanced diagnostics.<\/span><\/p>\n DealBridge designed a biosafety governance structure to support consistent implementation of containment policies. This framework included oversight committees, reporting mechanisms, and compliance monitoring processes.<\/span><\/p>\n The containment governance framework was developed through a structured milestone approach.<\/span><\/p>\n Evaluation of containment facilities, biosafety procedures, and laboratory practices.<\/span><\/p>\n Creation of pathogen risk categories and containment activity guidelines.<\/span><\/p>\n Development of standardized containment governance policies and operational rules.<\/span><\/p>\n Integration of containment governance policies into laboratory operations and national biosafety oversight structures.<\/span><\/p>\n The containment governance framework provided national authorities with clear operational guidance for managing laboratory activities across containment levels.<\/span><\/p>\n \u0627\u0644\u0646\u062a\u0627\u0626\u062c \u0627\u0644\u0631\u0626\u064a\u0633\u064a\u0629 \u062a\u0634\u0645\u0644:<\/span><\/p>\n These improvements enabled the laboratory system to manage biosafety risks more effectively while supporting both clinical diagnostics and advanced pathogen research.<\/span><\/p>\n High-containment laboratory environments require governance frameworks that connect biosafety policy with operational laboratory procedures.<\/span><\/p>\n Risk-based containment rules help ensure that laboratory activities involving infectious agents are performed within appropriate biosafety environments while maintaining operational flexibility.<\/span><\/p>\n DealBridge Global supports national health authorities and laboratory systems in developing biosafety governance models that strengthen safety, compliance, and preparedness for emerging biological threats.<\/span><\/p>","protected":false},"excerpt":{"rendered":" \u0627\u0644\u0627\u062d\u062a\u0648\u0627\u0621 \u0627\u0644\u062d\u0643\u0645<\/p>","protected":false},"author":1,"featured_media":12229,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[25,24],"tags":[],"class_list":["post-12194","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-post","category-listing-page"],"acf":[],"_links":{"self":[{"href":"https:\/\/dealbridgeglobal.com\/arb\/wp-json\/wp\/v2\/posts\/12194","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dealbridgeglobal.com\/arb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dealbridgeglobal.com\/arb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dealbridgeglobal.com\/arb\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dealbridgeglobal.com\/arb\/wp-json\/wp\/v2\/comments?post=12194"}],"version-history":[{"count":8,"href":"https:\/\/dealbridgeglobal.com\/arb\/wp-json\/wp\/v2\/posts\/12194\/revisions"}],"predecessor-version":[{"id":12364,"href":"https:\/\/dealbridgeglobal.com\/arb\/wp-json\/wp\/v2\/posts\/12194\/revisions\/12364"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dealbridgeglobal.com\/arb\/wp-json\/wp\/v2\/media\/12229"}],"wp:attachment":[{"href":"https:\/\/dealbridgeglobal.com\/arb\/wp-json\/wp\/v2\/media?parent=12194"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dealbridgeglobal.com\/arb\/wp-json\/wp\/v2\/categories?post=12194"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dealbridgeglobal.com\/arb\/wp-json\/wp\/v2\/tags?post=12194"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}\u0646\u0648\u0639 \u0627\u0644\u0645\u0634\u0627\u0631\u0643\u0629<\/h3>\n
DealBridge \u0627\u0644\u062e\u062f\u0645\u0627\u062a<\/h3>\n
\u0627\u0644\u062a\u0646\u0641\u064a\u0630\u064a \u0646\u0638\u0631\u0629 \u0639\u0627\u0645\u0629<\/h2>\n
\u0627\u0644\u0648\u0636\u0639<\/h2>\n
\u062c\u0648\u0647\u0631 \u0627\u0644\u062a\u062d\u062f\u064a<\/h2>\n
\u0639\u0644\u0649 DealBridge \u062c\u0633\u0631 \u0646\u0645\u0648\u0630\u062c<\/h2>\n
\u0627\u0644\u062a\u062d\u062f\u064a\u0627\u062a \u0627\u0644\u062a\u0634\u063a\u064a\u0644\u064a\u0629<\/h3>\n
\n<\/span> Unclear activity classification across containment levels<\/span>
\n<\/span> Distributed laboratory capabilities<\/span>
\n<\/span> Emerging pathogen preparedness requirements<\/span><\/p>\nDealBridge \u0627\u0644\u062c\u0633\u0631<\/h3>\n
\n<\/span> Standardized biosafety governance framework<\/span>
\n<\/span> Clear laboratory activity rules by containment level<\/span>
\n<\/span> National biosafety oversight structure<\/span><\/p>\n\u0646\u062a\u0627\u0626\u062c \u0627\u0644\u0639\u0645\u0644\u064a\u0627\u062a<\/h3>\n
\n<\/span> Improved biosafety compliance and risk management<\/span>
\n<\/span> Clear operational guidance for pathogen handling<\/span>
\n<\/span> Stronger national preparedness for high-risk pathogens<\/span><\/p>\n\u0639\u0644\u0649 \u0646\u0647\u062c DealBridge<\/h2>\n
Biosafety Capability Assessment<\/h3>\n
Pathogen Risk Classification<\/h3>\n
Containment Activity Rules<\/h3>\n
Governance and Oversight<\/h3>\n
\u0627\u0644\u062a\u064a \u062a\u0633\u064a\u0637\u0631 \u0639\u0644\u064a\u0647\u0627 \u0645\u0639\u0627\u0644\u0645<\/h2>\n
Phase 1 \u2013 Capability Assessment<\/h3>\n
Phase 2 \u2013 Risk Classification Development<\/h3>\n
Phase 3 \u2013 Policy Framework Design<\/h3>\n
Phase 4 \u2013 Implementation and Oversight<\/h3>\n
\u0627\u0644\u0646\u062a\u0627\u0626\u062c<\/h2>\n
\n
\n<\/span><\/li>\n
\n<\/span><\/li>\n
\n<\/span><\/li>\n\u0627\u0644\u0631\u0624\u064a\u0629 \u0627\u0644\u0627\u0633\u062a\u0631\u0627\u062a\u064a\u062c\u064a\u0629<\/h2>\n